J&J reports promising ebola vaccine data

Johnson & Johnson said on Monday its ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.

The two-dose regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants, the company said, citing data from a late-stage trial.

The regimen, Zabdeno and Mvabea, generated immune responses that persisted in adults for at least two years.